Two polymorphisms, rs6165 and rs6166 located in the intracellular domain of FSHR has been reported to affect folliculogenesis, steroidogenesis and oocyte maturation. Several studies have highlighted the role of FSHR polymorphisms in PCOS but the findings are conflicting. A meta-analysis was carried out to decipher the emerging perspectives.
Methodology
A comprehensive literature search was made using PubMed, PCOSkb, and Google Scholar. New Ottawa Scale has been utilized to evaluate the quality of each article. To evaluate the strength of association under different genetic models of rs6165 and rs6166 polymorphisms, odds ratio with a 95% confidence interval (CI) was calculated.
Results
A total of 20 articles were selected for the present study. In pooled analysis and after the stratification by ethnicity, polymorphism rs6165 remains unrelated to the onset of PCOS. Besides, rs6166 exhibits significant protection in the Indian population under recessive, additive, and allele models (OR = 0.7, CI: 0.54–0.9, p = 0.006, OR = 0.65, CI: 0.48–0.89, p = 0.006, OR = 0.82, CI: 0.7–0.95, p = 0.01, respectively) and low to moderate risk in the Caucasian population under allele model (OR = 1.17, CI: 1.04–1.32, p = 0.01).
Conclusion
This meta-analysis suggests that GG genotype of rs6166 provides protection against PCOS, in a population-specific manner.
Hinweise
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
PCOS
Polycystic Ovary Syndrome
LH
Luteinizing Hormone
ESHRE
European Society of Human Reproduction and Embryology
ASRM
American Society of Reproductive Medicine
FSH
Follicle Stimulating Hormone
GnRH
Gonadotropic Releasing Hormone
FSHR
Follicle Stimulating Hormone Receptor
LHCGR
Luteinizing Hormone/Choriogonadotropin Receptor
PCOSKB
Polycystic Ovary Syndrome Knowledge Base
MeSH
Medical Subject Headings
HWE
Hardy Weinberg Equilibrium
SNP
Single Nucleotide Polymorphism
NOS
New-Castle Ottawa Scale
PRISMA
Preferred Reporting Items for Systematic Reviews and Meta-Analysis
Polymerase Chain Reaction- Restriction Fragment Length Polymorphism
PCR-SSP
Polymerase Chain Reaction- Sequence Specific Priming
OR
Odds Ratio
CI
Confidence Interval
THADA
Thyroid Adenoma Associated
DENDD1A
DENN domain-containing protein 1A
Introduction
Polycystic ovary syndrome (PCOS) is a complex endocrine disorder affecting females of reproductive age and is the foremost cause of anovulatory infertility [1, 2]. The worldwide prevalence of PCOS is between 6 and 26% [3]. Chronic anovulation, hyperandrogenism, and menstrual irregularities are the characteristic features of PCOS [4], which are additionally accompanied by obesity, insulin resistance and high LH levels [5, 6]. The diagnosis of PCOS is based on Rotterdam criteria 2003 which states that 2 out 3 features: a) Oligo/anovulation, b) clinical or biochemical sign of hyperandrogenism, and c) presence of polycystic ovaries on ultrasonography should be present [7]. It is becoming evident that PCOS can affect a woman anytime. It may start while she is still in the womb and show clinical signs in adolescence which continue throughout her reproductive years. Moreover, even after menopause, PCOS women are more likely to develop metabolic diseases like diabetes, hypertension, and cardiovascular disease [8].
The precise etiology of PCOS is yet unknown, but it was suggested that the interplay of genetic and environmental factors is responsible for this condition [9]. In PCOS, the levels of gonadotropins such as follicle-stimulating hormone (FSH), luteinizing hormone (LH) and prolactin are abnormal. Due to persistently high-frequency GnRH stimulation, women with hyperandrogenic PCOS exhibit an increased LH pulse frequency and low FSH [10]. Lower FSH levels result in follicular development arrest, contributing to ovulatory dysfunction in PCOS. These alterations in gonadotropin secretion (LH and FSH) in PCOS may also depend on genetic variants of gonadotropic-related genes such as FSHR (FSH receptor) and LHCGR (LH/choriogonadotropin receptor) and are supported by various studies [11].
Anzeige
The FSHR is located on chromosome 2 at position p21–p16 and has 10 exons and 9 introns. The extracellular domain of the receptor is encoded by the first 9 exons. In contrast, the C-terminal end of the extracellular domain, the whole transmembrane domain, and the intracellular domain of the FSHR are all encoded by exon 10. In females, FSHR is expressed in granulosa cells and regulates the development of graffian follicles, granulosa cell proliferation and estrogen synthesis [12]. When FSH binds to its receptor, FSHR, it activates a number of intracellular signalling pathways, and for signal transduction exon 10 is crucial [13, 14]. Mutations in FSHR specifically in exon 10 can lead to the arrest of follicle development at several phases of growth and has several effects on phenotype such as variable development of secondary sex characteristics, primary amenorrhea, hypoplastic ovary and high serum levels of FSH [15, 16]. Ser680Asn (rs6166) and Ala307Thr (rs6165) are the two polymorphisms located in the exon 10 of FSHR and are well known to affect the efficacy of FSHR receptor towards its ligand (FSH), increase FSH levels in a compensatory manner. This increases FSHR resistance leading to reduce estrogen and inhibin B that establish the inhibitory feedback loop in the pituitary gland, resulting in hyperandrogenism which may arrest follicle development [17]. According to different studies, these polymorphisms may affect the menstrual cycle, ovarian hyperstimulation and PCOS development [18, 19]. Several studies have been carried out across the globe to e the genetic association of these SNPs but the results were conflicting. In order to resolve differences in genetic association research, meta-analysis has been a widely known method. It specifically incorporates findings from various studies on the same subject, improving statistical strength and accuracy in effect estimation [20]. Although, meta-analysis has already been done earlier on both variants [21‐23], however, there are some additional publications on FSHR polymorphisms [24, 25]. Furthermore, a recent meta-analysis by [23] includes only Asian studies. Hence, in order to ascertain the relationship between these polymorphisms and PCOS susceptibility in the global population, we further conducted a thorough and updated meta-analysis.
Material and methodology
Search strategy
Comprehensive computer-based literature searches on Google Scholar, PubMed, and PCOSkb were used to find each study that has reported the genetic association of Polycystic Ovary Syndrome and FSHR polymorphisms (rs6165 and rs6166) without any language barrier (up to March 2023). The following set of MeSH keywords and terms were used: Polycystic Ovary Syndrome or PCOS or Stein Leventhal Syndrome; FSHR or Follicle Stimulating Hormone Receptor or FSH; rs6165 or rs6166 or Ala307Thr or Ser680Asn; gene or allele or genotype or mutation or variant or variation or polymorphism or Genetic variant or Genetic variation. Moreover, manual screening was done on the reference lists of research articles and earlier meta-analyses.
Inclusion/ exclusion criteria
In this meta-analysis, studies fulfilling the following criteria were included: (a) a case–control design (b) evaluation of the association of rs6165 and rs6166 with PCOS (c) genotype frequency of controls in the Hardy Weinberg equilibrium (HWE) (d) provides genotypic data for both cases and control group (e) studies on human blood samples (f) published in the English language. Exclusion criteria were as follows: (a) not the case–control design, (b) Controls genotype frequency deviated from HWE (c) The design is based on family or sibling pairs (d) Animal studies.
Data search and quality assessment
Data were extracted from selected publications based on inclusion criteria. From each study, the following information was gathered: first Author name, year of publication, country of origin, diagnostic criteria of PCOS, method of genotyping, the total number of cases and controls and evidence of HWE in controls.
Anzeige
To check the quality of each publication included in the present meta-analysis New Castle Ottawa scale (NOS) [26] was used. NOS is based on a star scoring system and is categorized into three parts: a) Selection b) Comparability c) Outcome. For the non-randomized meta-analysis, each publication can be given a total of 9 stars, with 0 to 3 stars, 4 to 6 stars, and 7 to 9 stars representing low, moderate, and high quality, respectively. For the current meta-analysis, publications of moderate and high quality were chosen, while publications of low quality were excluded. Finally, PRISMA 2020 (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) checklist and flow diagram were used for this meta-analysis.
Statistical analysis
The power of the study was calculated using a Cats-power calculator which rendered the power to be > 95%. A goodness of fit Chi-square calculation was used to determine any deviations from HWE. Pooled odds ratios (OR) and 95% confidence intervals (CIs) were used to evaluate the strength of the association for the meta-analysis. The association was determined using the following four genetic models: dominant model (GG + AG vs. AA), recessive model (GG vs. AG + AA), additive model (GG vs. AA), and allele model (G vs. A). To assess heterogeneity, the I2 statistic was used and a random effect model (REM) was chosen when I2 was greater than 50%, indicating that heterogeneity is present, while a fixed effect model (FEM) was chosen when I2 was less than 50%, indicating that heterogeneity was absent. To assess publication bias, Beggs’s funnel plot was used. All data were analysed using Review Manager 5.4.1. Bonferroni correction was applied to p-value in order to reduce the type 1 error.
Results
Studies included in the meta-analysis
Figure 1 displays the flowchart for the search process and search results. A total of 156 possible studies were gathered through the use of database search and manual search. Titles and abstracts were carefully examined and 124 papers were eliminated, because they were duplicates, review articles, or case reports. Following full-text analysis, 10 were excluded since they were not case–control studies designed or have enough information for meta-analysis. In addition, two studies that deviated from Hardy Weinberg equilibrium were excluded, and one study was also taken out since it had a low NOS score. There were no additional relevant studies found despite our search of recent reviews and meta-analyses. Eventually, 20 case–control studies were selected for meta-analysis, and of these 20 studies, 16 were on Asians and 4 studies were on Caucasians. Table 1 enlists the distinguishing characteristics of all selected studies. Genotype frequency and HWE p-value of included studies were tabulated in Table 2.
Fig. 1
Flow diagram of the selection process for meta-analysis (according to PRISMA guidelines)
Table 1
List of included studies in the present meta-analysis
p-value < 0.05 considered as statistically significant
×
Pooled analysis
The findings of the meta-analysis were displayed in Table 3. For rs6165, fixed effect model was chosen for all the genetic models due to low heterogeneity. None of the genetic models confers a significant risk to PCOS in the overall analysis for rs6165 polymorphism (dominant model: OR = 1.04, CI: 0.93–1.16, p = 0.49; recessive model: OR-1.19 CI:1.03–1.3, p = 0.02; additive model: OR-1.2 CI:1.02–1.42, p = 0.03, allele model: OR = 1.07, CI: 0.99–1.18, p = 0.08 respectively) (Table 3; Fig. 2). Significant heterogeneity was observed for the rs6166 polymorphism in the allele, additive, and recessive models (I2 = 61%, 64%, 64%, respectively); however, genetic models did not indicate any risk for the development of PCOS (dominant model: OR = 1.05, CI:0.95–1.15, p = 0.34; Recessive model: OR = 0.97, CI:0.78–1.22, p = 0.82; Additive model: OR = 0.99, CI:0.76–1.29, p = 0.94; Allele model: OR = 1.02, CI: 0.90–1.15, p = 0.73) (Table 3, Fig. 3).
Table 3
Illustration of pooled and sub-group analysis under different genetic models
Overall Analysis
Asian Studies Meta-analysis
Indian Studies
Meta-analysis
Other studies Meta-analysis
FEM
REM
I2
rs6165
OR (CI), p-value
Dominant Model
1.04(0.93–1.16), 0.49
1.19 (0.92–1.16), 0.54
4%
1.04(0.92–1.18),
0.53
1.09(0.77–1.54),
0.63
0.6(0.25–1.47),
0.26
Recessive Model
1.19(1.03–1.3),
0.02
1.2 (1.01–1.4),
0.04
10%
1.22(1.02–1.46),
0.03
1.27(0.93–1.73),
0.13
0.64(0.3–1.33),
0.23
Additive Model
1.2(1.02–1.42),
0.03
1.19(0.96–1.47), 0.11
27%
1.23(1.02–1.49),
0.03
1.25(0.84–1.85),
0.16
0.48(0.18–1.34),
0.16
Allele Model
1.07(0.99–1.18), 0.08
1.07(0.97–1.17), 0.19
25%
1.07(0.97–1.19),
0.18
1.15(0.93–1.41),
0.19
0.7(0.43–1.14),
0.16
rs6166
Dominant Model
1.05(0.95–1.15),
0.34
1.04 (0.91–1.2)
0.56
44%
1.07 (0.95–1.2),
0.28
0.84 (0.66–1.06),
0.15
1.15 (0.95–1.39),
0.16
Recessive Model
1.02(0.91–1.15),
0.72
0.97 (0.78–1.22),
0.82
61%
1.11 (0.92–1.32),
0.27
0.7 (0.54–0.9),
0.006*
1.02 (0.91–1.15),
0.11
Additive Model
1.03 (0.90–1.2),
0.67
0.99 (0.76–1.29),
0.94
64%
1.1 (0.91–1.34),
0.33
0.65 (0.48–0.89),
0.006*
1.25 (0.98–1.59),
0.07
Allele Model
1.03(0.96–1.10),
0.4
1.02 (0.90–1.15),
0.78
64%
1.06 (0.95–1.15),
0.19
0.82 (0.7–0.95),
0.01*
1.17 (1.04–1.32),
0.01*
OR Odds Ratio, CI Confidence Interval, FEM Fixed Effect Model, REM Random Effect Model
*p-value was considered significant after Bonferroni correction,
Fig. 2
The association between FSHR (rs6165) variant and PCOS development using different genetic models in overall analysis: a Dominant model (GG + AG vs AA), b Recessive model (GG vs AG + AA), c Additive model (GG vs AA), d Allele model (G vs A). In each model, solid squares represent the OR and horizontal lines represent 95%CI and diamond represents the pooled OR and 95%CI
Fig. 3
The association between FSHR (rs6166) variant and risk of PCOS using different genetic models in overall analysis: a Dominant model (GG + AG vs AA), b Recessive model (GG vs AG + AA), c Additive model (GG vs AA), d Allele model (G vs A). In each model, solid squares represent the OR and horizontal lines represent 95%CI and diamond represents the pooled OR and 95%CI
×
×
Subgroup analysis
After the stratification by ethnicity, rs6165 polymorphism did not showed a significant risk of PCOS development in any ethnic group under any genetic model (Fig. 4; Table 3). In the Indian population, rs6166 polymorphism provides significant protection under recessive, additive, and allele models (Recessive model: OR = 0.7, CI:0.54–0.9, p = 0.006, Additive model: OR = 0.65, CI:0.48–0.89, p = 0.006, Allele model: OR = 0.82, CI:0.7–0.95, p = 0.01), while dominant model showed no association (Dominant model: OR = 0.84, CI:0.66–1.06, p = 0.15). Furthermore, a significant association was also found under the allelic model in other studies (Caucasian studies) (OR = 1.17, CI:1.04 -1.32, p = 0.01). However, none of the genetic models show any association with the Asian population (Table 3, Fig. 5).
Fig. 4
The association between FSHR (rs6165) and PCOS progression using different genetic models in Sub-group analysis: a Recessive model (GG vs AG + AA), b Additive model (GG vs AA). In each model, solid squares represent the OR and horizontal lines represent 95%CI and diamond represents the pooled OR and 95%CI
Fig. 5
The association between FSHR (rs6166) variant and PCOS risk using different genetic models in overall analysis: a Recessive model (GG vs AG + AA), b Additive model (GG vs AA), c Allele model (G vs A). In each model, solid squares represent the OR and horizontal lines represent 95%CI and diamond represents the pooled OR and 95%CI
×
×
Publication bias and sensitivity of meta-analysis
Begg’s funnel plots were used to analyze the publication bias in included studies and, because of their symmetrical design, neither of the studies showed any signs of publication bias. Leave one out sensitivity analysis was performed to check the stability of the study. After systematically excluding each study, statistically comparable results were still obtained, showing statistically valid findings from our meta-analysis.
Discussion
One of the most prevalent endocrine-metabolic disorders in women of reproductive age is PCOS and anovulation, infertility, and hyperandrogenism are its characteristic featu6res. PCOS is a polygenic condition, and numerous genetic variations are linked to its susceptibility [23]. The involvement of genetic factors in PCOS pathogenesis is evident in familial and genome-wide association studies (GWAS) [38, 41‐43]. FSHR, LHCGR, THADA, and DENND1A are PCOS-susceptibility loci [41, 44].
Chronic anovulation is a hallmark of PCOS and the mechanism by which follicle selection is blocked in PCOS is still not known. An abnormal endocrine environment may be responsible for the premature arrest of some follicles and the advancement of follicle maturation in others. The suppression of FSH is the primary cause of this “suspension” of follicle growth and it had been reported that after careful administration of low-dose FSH, growth and ovulation of a healthy dominant follicle was re-established [45‐48]. FSH performs by activating a specific receptor (FSHR) on the granulosa cells of the ovary. It was reported that phosphorylation of the Ser and Thr residues in the intracellular domain of FSHR may affect how the protein decouples from adenylyl cyclase. As a result, the function of the receptor, including the efficacy of FSH, may be affected by amino acid alterations linked to the corresponding SNPs (rs6165 and rs6166) [30, 49]. These two polymorphisms are located in exon 10 (rs6165 and rs6166) and are widely studied in different populations [4]; but the results had been inconsistent.
Anzeige
A meta-analysis is a statistical tool used to combine the findings of multiple studies on the same topic, increasing the statistical power to resolve discrepancies, and FSHR polymorphisms have already been meta-analyzed earlier as well [21, 22]. Additional studies on FSHR polymorphisms were found, after thoroughly reviewing the literature. Therefore, the present meta-analysis aims to investigate the association of FSHR exon 10 (rs6165 and rs6166) polymorphisms with PCOS risk. It comprises a total of 20 studies (Table 1). For rs6165, 14 studies were selected which include 2650 PCOS cases and 3226 controls and it was found that rs6165 does not exhibit an association with PCOS in any genetic model (Table 3). For rs6166, 19 studies with 3671 PCOS cases and 6579 controls were chosen and the protective role of Asn680Ser was observed in the Indian population under recessive, additive and allelic model while in the Caucasian population, it was demonstrated that Ser680 provides low to moderate risk under allelic model (OR-1.17, CI- 1.04–1.32, p = 0.01), however, in the Asian population, rs6166 polymorphism remained non-associated.
Chen et al. [21] conducted a meta-analysis on rs6165 and rs6166 that included 10 studies with 1720 PCOS cases and 4523 controls for rs6166 and 1097 cases and 1545 controls for rs6165. However, they did not observe any PCOS risk associated with FSHR polymorphisms. Another meta-analysis was carried out by Qiu et al. [22] with 11 studies on Thr307Ala (1326 cases and 3867 controls) and Asn680Ser (1344 cases and 3885 controls) and their study reported that Asn680Ser under homozygote model and Asn allele might have a protective effect against PCOS. In the sub-group analysis, the Asn680 allele showed a protective role only in Caucasians, not in Asian PCOS women. Wan et al. [23] also did a meta-analysis and they included 8 articles published on the Asian population. The results of a pooled meta-analysis in Asians supported that rs6166 polymorphism was strongly related to PCOS susceptibility. They also did a subsequent stratified study and observed that rs6165 remained unrelated to PCOS susceptibility in Chinese and Koreans, while rs6166 was related to PCOS susceptibility in Koreans but not in Chinese.
Conclusion
Our meta-analysis is the most comprehensive on the FSHR polymorphisms and PCOS risk. We scored each article using the Newcastle–Ottawa Quality Assessment Scale in order to find higher-quality publications, and each study included in the current meta-analysis received a rating of at least five. We examined all the included studies for fixed or random effect models and analyzed the total effects under dominant, recessive, additive, and allele models. This meta-analysis includes a higher number of studies than the earlier ones, thus it provides accurate estimation. In the present meta-analysis, it was concluded that polymorphism rs6166 was found to have a modest impact on PCOS, however, on a specific cohort. In a meta-analysis, if the degree of heterogeneity rises, it gets harder to justify an integrated conclusion. Heterogeneity for rs6166 polymorphism is higher despite of subgroup analysis, therefore these results cannot be generalized. Further studies on homogeneous and larger populations with ethnicity-matched controls are required to strengthen the statistical power and to better understand the role of FSHR polymorphisms with PCOS.
Acknowledgements
We are highly thankful to RUSA 2.0 for providing financial support.
Anzeige
Declarations
Ethics approval and consent to participate
NA.
Consent for publication
NA.
Competing interests
The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.
Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.
Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.
Welche Antibiotika darf man bei unkomplizierter Zystitis verwenden und wovon sollte man die Finger lassen? Welche pflanzlichen Präparate können helfen? Was taugt der zugelassene Impfstoff? Antworten vom Koordinator der frisch überarbeiteten S3-Leitlinie, Prof. Florian Wagenlehner.
Update Gynäkologie
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.
